Hyderabad: In the movement that will increase the production capacity of the Covid-19 vaccine developed by the original, Indian immunology (IIL) on Friday handed the first batch of covaxin drugs produced at the Karakapatla facility at the Genome Valley to Bharat Biotech.
The dose was submitted by the Implementing Director of Iil Dr.
K Anand Kumar to Bharat Biotech Chairman and Managing Director Dr.
Krishna Ella at the Genome Valley Iil facility.
According to sources, drug substances (important components of any vaccine) for around 1 million doses are submitted on Friday.
“We will begin to supply drug substances for 3-4 million covaxin doses per month from enrolled facilities and increase supplies up to 10 million doses per month on December 202 after special facilities for Covaxin becomes operational at Genome Valley,” Dr.
Anand.
Kumar said.
IIL and Bharat Biotech signed four agreements for Covaxin in April 2021 after that IIL utilizing the BSL-2 + anti-rabies vaccine facility in Karakapatla to make Covaxin in recording time and production began in July 2021.
“Batch produced in IIL manufacturing facilities.
Has Tested in BBIL and IIL and fulfill quality specifications.
The results are more than expected, “he said.
Calling the victory alliance for ‘Indian Team’, IIL MD said the company’s team worked tirelessly, all the time to meet the schedule and quality of the products committed.
“This is a proud moment for IIL to play an important role in supporting the interests of our nation during an unprecedented time,” he added.
DBT Secretary and Chairman of BIRAC Dr.
Renu Swarup called a loan license agreement by CDSCO for IIL to produce covaxin drug as a major milestone achieved in a very short time span.
IIL approved HIS 60 Crore grant to improve production capabilities as part of the Surakha Covid mission.